Bromocriptine Mesylate

Catalog No.S4309 Batch:S430904

Print

Technical Data

Formula

C32H40BrN5O5.CH4O3S
Molecular Weight 750.7 CAS No. 22260-51-1
Solubility (25°C)* In vitro DMSO 100 mg/mL (133.2 mM)
Ethanol 100 mg/mL (133.2 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.8mg/ml Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Bromocriptine mesylate is a dopamine receptor agonist with a Ki of 12.2 nM for D3 receptor and D2 receptor and a Ki of 1659 nM, 59.7 nM, 1691 nM for D1 receptor, D4 receptor, and D5 receptor, respectively. Bromocriptine mesylate is used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly.
Targets
D2 receptor [1] D3 receptor [1] D4 receptor [1] D1 receptor [1] D5 receptor [1]
12.2 nM(Ki) 12.2 nM(Ki) 59.7 nM(Ki) 1659 nM(Ki) 1691 nM(Ki)
In vitro

Bromocriptine dose-dependently reduces the number of OH radicals. [1] Bromocriptine has a strong scavenging effect on the 5,5-dimethyl-1-pyrroline-N-oxide hydroxide signal produced from Fenton's reaction. Bromocriptine also attenuates the stable free radical diphenyl-p-picrylhydrazyl signal. [2]
In vivo

Bromocriptine (5 mg/kg, i.p., 7 days) completely protects against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine. [1] Bromocriptine (2.5 mg/kg, i.p., daily for 3 days) significantly reduces autooxidation of brain homogenates collected from rats. [2] Bromocriptine (12.5 mg/kg) produces mild dyskinesia over the course of the study that is significantly less severe than in the L-dopa-treated group in the MPTP-treated marmoset. Bromocriptine, has a lesser tendency than L-dopa to produce dyskinesia while similarly improving motor performance in drug-naive MPTP-treated marmosets. [3] Bromocriptine (10 μM and 10 mg/kg i.p.) blocks .OH formation caused by MPTP in vitro (20 μM) and in vivo (30 mg/kg i.p.) in mice. Bromocriptine reduces an MPTP-induced increase in the activity of catalase and superoxide dismutase in substantia nigra on the seventh day. Bromocriptine blocks MPTP-induced behavioral dysfunction as well as glutathione and dopamine depletion, indicating its potent neuroprotective action. [4]

Protocol (from reference)

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.